XNAS · Healthcare · Biotechnology
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Q1 2026 | -0.83 | -1.26 | -51.81% | $191.2M | ❌ Miss | +1.20% | -3.23% | +4.38% |
| 2026-02-23 | Q4 2025 | -0.72 | -0.56 | +22.22% | $196.0M | ✅ Beat | +0.15% | -4.80% | -7.43% |
| 2025-11-03 |
| Q3 2025 |
| -0.87 |
| -0.68 |
| +21.84% |
| $171.0M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-04 | Q2 2025 | -1.05 | -0.47 | +55.66% | $150.0M | ✅ Beat | +5.79% | -2.42% | +14.51% |
| 2025-02-18 | Q4 2024 | -0.99 | -0.80 | +19.19% | $118.8M | ✅ Beat | -0.88% | -0.78% | -1.42% |
| 2024-11-12 | Q3 2024 | -1.41 | -0.49 | +65.25% | $104.8M | ✅ Beat | -1.67% | -4.05% | -5.15% |
| 2024-05-06 | Q1 2024 | -1.21 | -1.00 | +17.36% | $75.0M | ✅ Beat | +1.32% | -0.40% | -2.44% |
| 2024-02-20 | Q4 2023 | -1.15 | -0.73 | +36.52% | $71.5M | ✅ Beat | — | — | — |
Showing last 8 quarters.